A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) ...

The Christie NHS Foundation Trust together with the Cancer Research UK National Biomarker Centre and The University of ...

MoleMap take high-resolution photos of customers’ bodies to map, diagnose and monitor the development of lesions – in an ...

TIL-IMP therapy offers sustained QoL benefits over ipilimumab in advanced melanoma, supporting its role in personalized care.

How woman beats terminal cancer after doctors gave up hope. Sarah Martinez's incredible journey will inspire you to never ...

We're talking with Dr. Richard Miller, founder of Bay Dermatology, at their Downtown St. Pete location to discuss Mohs ...

A new study led by researchers at Lund University in Sweden reveals that melanoma can, in some cases, be driven by ...

While melanoma primarily affects people with fair skin, it can affect anyone, according to plastic surgeon, Dr. Srikanth ...

Researchers studied the progression-free and overall survival rates of patients with advanced melanoma after cessation of immune checkpoint inhibitor therapy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Like other cancers, melanoma is rising among young adults. It's now the 2nd most common cancer in 15 to 39 year-olds.